The International Research Based Pharmaceutical Manufacturers Association (IRPMA), composed of multinational R&D pharmaceutical manufacturers and aiming at improving the overall pharmaceutical environment. Facing the foreseeable challenges, IRPMA committees are going to employ outstanding industry talents working under a functional based organization to exert for the pharmaceutical industry on the issues critical to the development of the pharmaceutical industry.

Three Functional Committees:

  • Medical & Regulatory Affairs Committee
    • Establish a transparent, efficient and reasonable system for regulatory applications in Taiwan.
    • Accelerate the internationalization of the drug regulation by establishing guidelines that are in line with international requirements for clinical trial protocol and new drug approvals.
  • Market Access Committee
    • To secure a reasonable NHI payment scheme and establish an explicit drug pricing policy.
    • Enhance patients’ right of drug accessibility.
  • Public Affairs & Communication Committee
    • Enhance IRPMA's image and reputation. Clearly explain and communicate IRPMA's principles and positions to related stakeholders.
    • External Communication
      • Strengthen communication on value of innovative medicine
      • Facilitate positive policy change on new drug price and review process
      • IRPMA Code of Marketing Practices
      • Public educations on proper drug usage
      • Convey IRPMA's position and consideration toward government's regulation and policy
    • Internal Communication
      • Monthly committee meeting to facilitate internal communication on key topics among the working committees, and to build consensus among member companies
      • Provide daily news clipping to member companies focusing on healthcare related information and government policy

Talent Pool Working Groups:

  • Cross-Strait Affairs Working Group
  • Finance and Administration Working Group
  • Legal and IP Working Group
  • SPD Working Group